These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 17889722)

  • 1. Characterization of in vitro growth of multiple myeloma cells.
    Zlei M; Egert S; Wider D; Ihorst G; Wäsch R; Engelhardt M
    Exp Hematol; 2007 Oct; 35(10):1550-61. PubMed ID: 17889722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
    Giuliani N; Colla S; Morandi F; Rizzoli V
    Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
    Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival.
    Ge Y; Zhan F; Barlogie B; Epstein J; Shaughnessy J; Yaccoby S
    Br J Haematol; 2006 Apr; 133(1):83-92. PubMed ID: 16512833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
    Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
    Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
    Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
    Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of the osteoclast in pathogenesis of multiple myeloma].
    Zhang JH; Fu JX; Zhang XH; Sun Y
    Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):323-6. PubMed ID: 17877161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
    Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
    Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Requirement of soluble factors produced by bone marrow stromal cells on the growth of novel established human myeloma cell line.
    Aikawa S; Hatta Y; Tanaka M; Kaneita Y; Yasukawa K; Sawada U; Horie T; Tsuboi I; Aizawa S
    Int J Oncol; 2003 Mar; 22(3):631-7. PubMed ID: 12579318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.
    Fuhler GM; Baanstra M; Chesik D; Somasundaram R; Seckinger A; Hose D; Peppelenbosch MP; Bos NA
    Exp Cell Res; 2010 Jul; 316(11):1816-28. PubMed ID: 20307537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
    Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
    Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokines and signal transduction.
    Hideshima T; Podar K; Chauhan D; Anderson KC
    Best Pract Res Clin Haematol; 2005; 18(4):509-24. PubMed ID: 16026734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
    Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
    J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells.
    Huang H; Wu D; Fu J; Chen G; Chang W; Chow HC; Leung AY; Liang R
    Eur J Haematol; 2009 Sep; 83(3):191-202. PubMed ID: 19467017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients.
    Kuranda K; Berthon C; Dupont C; Wolowiec D; Leleu X; Polakowska R; Jouy N; Quesnel B
    Exp Hematol; 2010 Feb; 38(2):124-31. PubMed ID: 19948206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.
    Tanaka Y; Abe M; Hiasa M; Oda A; Amou H; Nakano A; Takeuchi K; Kitazoe K; Kido S; Inoue D; Moriyama K; Hashimoto T; Ozaki S; Matsumoto T
    Clin Cancer Res; 2007 Feb; 13(3):816-23. PubMed ID: 17289872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The significance of IGF-1, VEGF, IL-6 in multiple myeloma progression].
    Guo YQ; Chen SL
    Zhonghua Xue Ye Xue Za Zhi; 2006 Apr; 27(4):231-4. PubMed ID: 16875552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
    Katodritou E; Terpos E; North J; Kottaridis P; Verrou E; Gastari V; Chadjiaggelidou C; Sivakumaran S; Jide-Banwo S; Tsirogianni M; Kapetanos D; Zervas K; Lowdell MW
    Am J Hematol; 2011 Dec; 86(12):967-73. PubMed ID: 21919039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factors.
    Zannettino AC; Farrugia AN; To LB; Atkins GJ
    Methods Mol Med; 2005; 113():245-56. PubMed ID: 15968108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect.
    Corso A; Ferretti E; Lunghi M; Zappasodi P; Mangiacavalli S; De Amici M; Rusconi C; Varettoni M; Lazzarino M
    Cancer; 2005 Jul; 104(1):118-25. PubMed ID: 15895374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.